PROCARDIA XL (nifedipine) by Pfizer is calcium channel antagonists [moa]. First approved in 1989.
Drug data last refreshed 2d ago
Procardia XL is an extended-release oral tablet containing nifedipine, a dihydropyridine calcium channel blocker that works by inhibiting calcium influx into vascular smooth muscle cells. It is indicated for hypertension and high blood pressure variability, with off-label use in premature labor, postpartum hypertension, and altitude-related conditions. The drug reduces peripheral vascular resistance and blood pressure through its mechanism as a calcium channel antagonist.
As a mature, approaching LOE product with modest Medicare spending ($2M), Procardia XL teams are likely focused on defensive positioning and cost management rather than expansion.
Calcium Channel Antagonists
Dihydropyridine Calcium Channel Blocker
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil
Effectiveness and Tolerability of Long-Acting Nifedipine Gastrointestinal Therapeutic System in Chronic Kidney Disease With Uncontrolled Hypertension Patients, a Prospective, Multicenter, Observational Study
Comparison of Nifedipine Versus Indomethacin for Acute Preterm Labor
Nifedipine GITS and Amlodipine Besylate on Recovery of Blood Pressure Rhythm and Arterial Stiffness
Effect of Nifedipine GITS in Patients With Mild-to-moderate Primary Hypertension
Worked on PROCARDIA XL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moProcardia XL currently shows zero linked job openings, reflecting its mature lifecycle and modest commercial scale. Career positions associated with this product are likely in legacy brand management, field teams, or compliance roles rather than growth-focused commercial or medical functions.